Important note: Information in this article was accurate in October 2007. The state of the art may have changed since the publication date.
EMEA recommends reinstating license for Roche’s nelfinavir
HIV Treatment Bulletin - Vol. 8, No. 10, October 2007
On 20 September 2007, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the lifting of the suspension of the marketing authorisation for nelfinavir (Viracept, manufacutred by Roche) and the re-introduction of the medicine onto the market in the European Union.
The marketing authorisation for Viracept was suspended on 6 August 2007, following the contamination during the manufacturing process of several batches of the active substance with ethyl mesilate, a known genotoxic substance. See previous Treatment Alerts in the previous two issues of HIV Treatment Bulletin. [1, 2].
The CHMP has assessed the corrective and preventive measures put in place by Roche, and these have also been verified by an inspection of the manufacturing site. As a result, the CHMP has been reassured that the cause of the contamination has been eliminated and that future production of Viracept would meet the required quality standards. The CHMP therefore decided to recommend to the European Commission the lifting of the marketing authorisation suspension.
Once this decision has been issued – this is not expected before the end of October – Roche will be able to resume supply of Viracept to patients. It is likely to take several months for nelfinavir to become available again. Countires in most need will be prioritised for the first supply.
Source: EMEA press release.
Nelfinavir reinstatement - EMEA press release PDF Open link in new window http://www.emea.europa.eu/pdfs/general/direct/pr/41816807en.pdf
References
2007-10-10
IB070810-09
©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.